Evaluation of HLA-B*5701 screening prior to abacavir administration for prevention of the hypersensitivity reaction.
Phase 3
- Conditions
- HIV infection
- Registration Number
- JPRN-UMIN000003095
- Lead Sponsor
- Department of Pharmacy, University of Fukui Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients received abacavir once, or with severe hepatic dysfunction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of abacavir-hypersensitive patients to the HLA-B*5701-negative.
- Secondary Outcome Measures
Name Time Method